All Cowlpane coverage tagged venture capital, sourced from global financial publications and updated continuously.
VCs are betting on overstated ARR, with up to 30% of AI founders padding metrics, raising valuation risk for early‑stage backers.
In just 72 hours, Anthropic and OpenAI rolled out enterprise AI platforms and secured marquee financial‑services deals, forcing investors to reassess AI startup valuations.
New rules bar U.S. researchers from publishing with certain foreign partners, forcing AI developers to rethink collaboration and market timelines.
AI service rates plunged in April 2026, forcing developers to rethink cost structures and funding timelines.
Nvidia poured $18.6 billion into venture bets this quarter and now projects $20 billion in CPU sales, tightening the link between its chip empire and partner health.
RFK Jr.’s anti‑mammogram campaign sparked a wave of physician backlash, threatening AI health‑tech startups that rely on preventive‑care data.
The U.S. Commerce Department poured $2.013 billion into quantum projects, reshaping the competitive landscape for AI‑driven developers.
Convective Capital unveiled an $85 million disaster‑resilience fund, signaling a shift that forces AI‑focused founders to embed climate safeguards now.
Climate firms are racing into rare‑earth mining as U.S. policy stalls, opening new revenue streams for tech investors.
SpaceX disclosed its finances for the first time, hinting at a market size that dwarfs every previous industry.
Sam Altman pledged OpenAI tokens to every Y Combinator batch, turning AI access into a direct equity play for early‑stage founders.
SpaceX’s S‑1 filing reveals a $137 billion valuation, setting a new benchmark for capital‑intensive tech ventures.
Exa Labs closed a $250 million round at a $2.2 billion valuation, signaling a new wave of capital for AI‑driven search infrastructure.
NanoCo turns down a $20M acquisition offer to raise $12M in seed funding, signaling a high-stakes bet on secure, open-source agentic AI.
Two AI‑driven assistants generated and vetted dozens of drug‑repurposing hypotheses, accelerating early‑stage pipelines for developers.
